Key facts
- This page summarizes David Owens's Form 4 filing for Nexalin Technology, Inc. (NXL).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Dec 2025, 09:41.
David Owens - 19 Dec 2025 Form 4 Insider Report for Nexalin Technology, Inc. (NXL)
- Reporting relationship
- Chief Medical Officer, Director
- Issuer ticker
- NXL
- Reported as of
- 19 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2025, 09:41:08 UTC
- Prior SEC filing
- 30 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Owens Name: David Owens, M.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Owens filed Form 4 for Nexalin Technology, Inc. (NXL) on 23 Dec 2025.
Change
- Previous filing in this sequence was filed on 30 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001916664
Primary reporting owner
Owens David
- Relationship
- Chief Medical Officer, Director
- Address
- 4545 HARRIS TRAIL NW, ATLANTA
- Signature
- /s/ David Owens Name: David Owens, M.D.
- Signature date
- 23 Dec 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NXL
transaction
Derivative
Stock Option (right to buy)*
Award
- Transaction value
- $0
- Shares
- +1,000,000
- Change %
- +67%
- Price
- $0.000000
- Shares after
- 2,484,809
- Date
- 19 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $0.8300
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
*Granted under the 2023 Equity Incentive Plan, subject to Shareholder Approval to increase the Plan limit under NASDAQ Rules.